Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Reed Miller
The companies signed a deal to allow Novo Nordisk’s smart insulin pens to share insulin dosing data with Medtronic’s continuous glucose monitoring devices. Novo Nordisk's smart insulin pens are already compatible with all other major brands of continuous glucose monitors.
Results of the 120-patient, sham-controlled REDUCE FMR trial showed Cardiac Dimensions Carillon device can significantly reduce mitral regurgitation and left ventricular volume in patients with symptomatic functional mitral regurgitation.
Results of a study in over 11,000 patients shows Abbott’s MI3 algorithm can risk-stratify patients with suspected myocardial infarction and help doctors decide which patients are most likely to benefit from earlier clinical decisions.
The In.Pact AV paclitaxel-coated balloon outperformed plain angioplasty balloons in the IN.PACT AV Access trial, the first large, multi-center randomized trial comparing a drug-coated balloon to standard balloon angioplasty in the treatment of hemodialysis arteriovenous access stenoses.
Dreem 2 is a biofeedback headband with seven sensors that measure brain activity, heart rate, respiration and movement that works with a mobile app to help users improve the quality of their sleep.
The US FDA has approved r-SNM sacral neuromodulation system for treating chronic fecal incontinence and Axonics expects the agency to approve it for overactive bladder and urinary retention in the next few weeks. The company expects r-SNM to compete with Medtronic's Interstim non-rechargeable sacral neuromodulation system.